Blastocystis
Blastocystis Infections
Sikkim
Intestinal Diseases, Parasitic
Blastocystis hominis
Encyclopedias as Topic
Irritable Bowel Syndrome
Isolate resistance of Blastocystis hominis to metronidazole. (1/54)
Isolates of Blastocystis hominis from infected immigrant workers from Indonesia, Bangladesh and infected individuals from Singapore and Malaysia were assessed for growth pattern and degree of resistance to different concentrations of metronidazole. Viability of the cells was assessed using eosin-brillian cresyl blue which stained viable cells green and nonviable cells red. The Bangladeshi and Singaporean isolates were nonviable even at the lowest concentration of 0.01 mg/ml, whereas 40% of the initial inoculum of parasites from the Indonesian isolate at day one were still viable in cultures with 1.0 mg/ml metronidazole. The study shows that isolates of B. hominis of different geographical origin have different levels of resistance to metronidazole. The search for more effective drugs to eliminate th parasite appears inevitable, especially since surviving parasites from metronidazole cultures show greater ability to multiply in subcultures than controls. (+info)Intestinal blockage by carcinoma and Blastocystis hominis infection. (2/54)
We detected heavy infections of Blastocystis hominis in four individuals with intestinal obstruction due to cancerous growths. After surgery, the infections spontaneously resolved, without specific chemotherapy. It appears that the B. hominis infection was coincidental and not related to the neoplastic growth. We suggest that intestinal obstruction and concomitant stool retention, plus hemorrhage from cancerous lesions, may have permitted the more abundant growth of B. hominis. This is the first report of a possible relationship between intestinal obstruction and a concomitant B. hominis infection. (+info)Genomic analysis of Blastocystis hominis strains isolated from two long-term health care facilities. (3/54)
The genotype Blastocystis hominis is highly polymorphic. Therefore, a genetic marker would be a powerful tool for the identification or classification of B. hominis subtypes and could be used as a means to resolve the transmission route or origin of the parasite. To this end, 32 B. hominis isolates were collected from patients and/or staff members of two long-term health care facilities (facilities A and B), and these organisms were subjected to genotype analysis based on diagnostic PCR primers and restriction fragment length polymorphism (RFLP) of small subunit rRNA gene (rDNA). Based on PCR amplification using diagnostic primers which were developed from randomly amplified polymorphic DNA analysis of known strains of B. hominis, the 32 isolates of B. hominis were classified into three different subtypes. Thirty isolates, including twenty-four that were isolated from patients and a staff member, from facility A and all isolates isolated from six patients from facility B showed the same genotype. Two of six patients of facility B had been transferred from facility A, and these two patients also had the same-genotype B. hominis that corresponded to 24 isolates from facility A. This genotype strain may have been transmitted by these two patients from facility A to facility B, suggesting human-to-human transmission. In contrast, 2 of 26 isolates from facility A showed distinct genotypes, suggesting that the colonization by these two isolates is attributable to another infectious route. These different subtypes were subjected to RFLP analysis, and the RFLP profiles were correlated with the results obtained by diagnostic PCR primers. This study presents the first molecular evidence of possible human-to-human B. hominis infection between and/or among two small communities. (+info)Clinical significance and frequency of Blastocystis hominis in Turkish patients with hematological malignancy. (4/54)
The effect of Blastocystis hominis (B. hominis) in both immunocompetent and immunocompromised subjects has been the subject of debate in recent years, mostly in response to its unknown pathogenicity and frequency of occurrence. We performed a non-randomised, open labelled, single institute study in our hospital in order to investigate the clinical significance and frequency of B. hominis in patients suffering from hematological malignancy (HM) who displayed symptoms of gastrointestinal diseases during the period of chemotherapy-induced neutropenia. The presence and potential role of other intestinal inclusive of parasites were also studied. At least 3 stool samples from each of 206 HM patients with gastrointestinal complaints (the HM group) were studied. These were compared with stool samples from a control group of 200 patients without HM who were also suffering from gastrointestinal complaints. Samples were studied with saline-lugol, formalin-ether, and trichome staining methods. Groups were comparable in terms of gender, age and type of gastrointestinal complaints. In the HM group, the most common parasite was B. hominis. In this group, 23 patients (13%) had B. hominis, while in the control group only 2 patients (1%) had B. hominis. This difference was statistically significant (P < 0.05). Symptoms were non-specific for B. hominis or other parasites in the HM group. The predominant symptoms in both groups were abdominal pain (87-89.5%), diarrhea (70-89.5%), and flatulence (74-68.4%). Although all patients with HM were symptom-free at the end of treatment with oral metranidazol (1,500 mg per day for 10 days) 2 patients with HM had positive stool samples containing an insignificant number of parasites (< 5 cells per field). In conclusion, it appears that B. hominis is not rare and should be considered in patients with HM who have gastrointestinal complaints while being treated with chemotherapy. Furthermore, metranidazol appears to be effective in treating B. hominis infection. (+info)Ribodemes of Blastocystis hominis isolated in Japan. (5/54)
To determine if genetic diversity of Blastocystis hominis exists in Japan, we monitored 64 B. hominis-infected people: 39 asymptomatic people whose infections were detected during routine medical check-ups (32 Japanese and 7 non-Japanese) and 25 patients with gastrointestinal symptoms who visited the outpatient clinics of St. Luke's International Hospital (19 Japanese and 6 non-Japanese). We detected 6 known and 2 new riboprint patterns in isolates from the infected people. There were no differences in the distribution of ribodemes between isolates from Japanese and non-Japanese people, similar to that in other countries. However, we noted a possible relationship between ribodeme type and pathogenicity. The results suggest that ribodemes I, III, and VI may be responsible for gastrointestinal symptoms. (+info)Epidemiological survey of Blastocystis hominis in Huainan City, Anhui Province, China. (6/54)
AIM: To provide scientific evidence for prevention and controlling of blastocystosis, the infection of Blastocystis homonis and to study its clinical significance in Huainan City, Anhui Province, China. METHODS: Blastocystis homonis in fresh stools taken from 100 infants, 100 pupils, 100 middle school students and 403 patients with diarrhea was smeared and detected with method of iodine staining and hematoxylin staining. After preliminary direct microscopy, the shape and size of Blastocystis homonis were observed with high power lens. The cellular immune function of the patients with blastocystosis was detected with biotin-streptavidin (BSA). RESULTS: The positive rates of Blastocystis homonis in fresh stools taken from the infants, pupils, middle school students and the patients with diarrhea, were 1.0 % (1/100), 1.0 % (1/100), 0 % (0/100) and 5.96 % (24/403) respectively. Furthermore, the positive rates of Blastocystis homonis in the stool samples taken from the patients with mild diarrhea, intermediate diarrhea, severe diarrhea and obstinate diarrhea were 6.03 % (14/232), 2.25 % (2/89), 0 % (0/17) and 12.31 % (8/65) respectively. The positive rates of Blastocystis homonis in fresh stools of male and female patients with diarrhea were 7.52 % (17/226) and 3.95 % (7/177) respectively, and those of patients in urban and rural areas were 4.56 % (11/241) and 8.02 % (13/162) respectively. There was no significant difference between them (P>0.05). The positive rates of CD(3)(+), CD(4)(+), CD(8)(+) in serum of Blastocystis homonis-positive and-negative individuals were 0.64+/-0.06, 0.44+/-0.06, 0.28+/-0.04 and 0.60+/-0.05, 0.40+/-0.05 and 0.30+/-0.05 respectively, and the ratio of CD(4)(+)/CD(8)(+) of the two groups were 1.53+/-0.34 and 1.27+/-0.22. There was significant difference between the two groups (P<0.05, P<0.01). CONCLUSION: The prevalence of Blastocystis hominis as an enteric pathogen in human seems not to be associated with gender and living environment, and that Blastocystis hominis is more common in stool samples of the patients with diarrhea, especially with chronic diarrhea or obstinate diarrhea. When patients with diarrhea infected by Blastocystis hominis, their cellular immune function decreases, which make it more difficult to be cured. (+info)Clinical characteristics and endoscopic findings associated with Blastocystis hominis in healthy adults. (7/54)
Ninety-nine individuals with stools positive for Blastocystis hominis but negative for other parasites were identified from medical records of healthy adults who had received a physical examination at Taipei Veterans General Hospital from November 2000 to October 2002. The medical records of these 99 positive cases and 193 randomly selected controls, matched for age, sex, and date of examination, were retrospectively reviewed. The pathogenicity of B. hominis could not be demonstrated due to a lack of association with the development of gastrointestinal symptoms or pathologic findings on endoscopic examination. Multivariate analyses revealed that chronic hepatitis B infection was a predisposing condition to the acquisition of B. hominis (odd ratio = 2.848, 95% confidence interval = 1.299-6.242, P = 0.009), and concentration of urate was significantly lower in B. hominis-positive individuals (mean +/- SD = 361.64 +/- 87.44 versus 392.57 +/- 93.38 micromol/L; P = 0.009). Among the 64 individuals who underwent gastric biopsy, Helicobacter pylori was found more frequently in the individuals harboring B. hominis (19 of 26 versus 15 of 38; P = 0.017). (+info)Irritable bowel syndrome: in search of an etiology: role of Blastocystis hominis. (8/54)
This study was designed to examine stool specimens of irritable bowel syndrome (IBS) patients for Blastocystis hominis, a common intestinal parasite. One hundred fifty patients were enrolled, 95 IBS cases and 55 controls. These patients provided a medical history, and underwent physical and laboratory evaluations that included stool microscopy and culture for B. hominis and colonoscopy. The 95 cases (51 males and 44 females) had a mean +/- SD age of 37.8 +/- 13.2 years. Stool microscopy was positive for B. hominis in 32% (30 of 95) of the cases and 7% (4 of 55) of the controls (P = 0.001). Stool culture was positive in 46% (44 of 95) of the cases and 7% (4 of 55) of the controls (P < 0.001). Stool culture for B. hominis in IBS was more sensitive than microscopy (P < 0.001). Blastocystis hominis was frequently demonstrated in the stool samples of IBS patients; however, its significance in IBS still needs to be investigated. Stool culture has a higher positive yield for B. hominis than stool microscopy. (+info)A Blastocystis is a single-celled microscopic organism (protozoan) that can inhabit the human gastrointestinal tract. It is found in the stool of infected individuals and is classified as a stramenopile, which is a group of organisms that also includes algae and water molds.
Blastocystis is often considered a commensal organism, meaning that it can live in the human gut without causing any harm. However, some studies have suggested that Blastocystis may be associated with gastrointestinal symptoms such as diarrhea, abdominal pain, and bloating, particularly in people with compromised immune systems or other underlying health conditions.
There is ongoing debate among researchers about the role of Blastocystis in human health, and more research is needed to fully understand its impact on the gut microbiome and overall health. Currently, there is no consensus on whether or not to treat Blastocystis in asymptomatic individuals.
A Blastocystis infection is a condition caused by the presence and reproduction of the single-celled microscopic parasite, Blastocystis spp., in the human gastrointestinal tract. This organism is commonly found in the stool of both healthy individuals and those with gastrointestinal symptoms. The exact role of Blastocystis in human health and disease is not well understood, but its presence has been associated with a range of intestinal symptoms such as diarrhea, abdominal discomfort, bloating, and nausea.
Infection occurs through the ingestion of Blastocystis cysts, usually via contaminated food or water, or directly from contact with infected individuals or animals. Once inside the human body, the parasite transforms into its active form, multiplies, and sheds cysts in the stool, continuing the transmission cycle.
Diagnosis of Blastocystis infection is typically made through microscopic examination of stool samples, where the presence of the parasite can be detected. In some cases, more advanced diagnostic techniques like PCR or DNA sequencing may be used to identify the specific Blastocystis subtype involved.
Treatment for Blastocystis infections is often not necessary for asymptomatic individuals, as the organism can sometimes coexist harmoniously within the gastrointestinal tract without causing any issues. However, for those experiencing persistent or severe symptoms, antiparasitic medications like metronidazole or tinidazole may be prescribed to help eliminate the infection. Maintaining good hygiene practices and avoiding potential sources of contamination can also help prevent Blastocystis infections.
I'm sorry for any confusion, but "Sikkim" is not a medical term. It is actually the name of a state in India, located in the northeastern part of the country. If you have any questions about medical terminology or concepts, I'd be happy to try and help answer those for you!
Parasitic intestinal diseases are disorders caused by microscopic parasites that invade the gastrointestinal tract, specifically the small intestine. These parasites include protozoa (single-celled organisms) and helminths (parasitic worms). The most common protozoan parasites that cause intestinal disease are Giardia lamblia, Cryptosporidium parvum, and Entamoeba histolytica. Common helminthic parasites include roundworms (Ascaris lumbricoides), tapeworms (Taenia saginata and Taenia solium), hookworms (Ancylostoma duodenale and Necator americanus), and pinworms (Enterobius vermicularis).
Parasitic intestinal diseases can cause a variety of symptoms, including diarrhea, abdominal pain, bloating, nausea, vomiting, fatigue, and weight loss. The severity and duration of the symptoms depend on the type of parasite, the number of organisms present, and the immune status of the host.
Transmission of these parasites can occur through various routes, including contaminated food and water, person-to-person contact, and contact with contaminated soil or feces. Preventive measures include practicing good hygiene, washing hands thoroughly after using the toilet and before handling food, cooking food thoroughly, and avoiding consumption of raw or undercooked meat, poultry, or seafood.
Treatment of parasitic intestinal diseases typically involves the use of antiparasitic medications that target the specific parasite causing the infection. In some cases, supportive care such as fluid replacement and symptom management may also be necessary.
'Blastocystis hominis' is a species of microscopic single-celled organisms (protozoa) that can inhabit the human gastrointestinal tract. It is often found in the stool of both healthy individuals and those with gastrointestinal symptoms. The role of 'Blastocystis hominis' as a pathogen or commensal organism remains a subject of ongoing research and debate, as some studies have associated its presence with various digestive complaints such as diarrhea, abdominal pain, and nausea, while others suggest it may not cause any harm in most cases.
Medical professionals typically do not consider 'Blastocystis hominis' a primary pathogen requiring treatment unless there is clear evidence of its involvement in causing symptoms or if the individual has persistent gastrointestinal issues that have not responded to other treatments. The recommended treatment, when necessary, usually involves antiprotozoal medications such as metronidazole or tinidazole. However, it's essential to consult a healthcare professional for an accurate diagnosis and appropriate treatment plan.
An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.
Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent abdominal pain, bloating, and altered bowel habits in the absence of any structural or biochemical abnormalities. The symptoms can vary from person to person, ranging from mild to severe.
The exact cause of IBS is not known, but it's thought to involve a combination of factors such as muscle contractions in the intestine, abnormalities in the nervous system, inflammation in the intestines, severe infection, or changes in bacteria in the gut.
It's important to note that while IBS can cause great discomfort and distress, it does not lead to serious complications such as changes in bowel tissue or increased risk of colorectal cancer. However, it can significantly affect a person's quality of life and daily activities.
"Strongyloides ratti" is a species of parasitic roundworm that infects the intestines of laboratory rats. The adult female worm lives in the mucosa of the small intestine, where it lays eggs that hatch into larvae. These larvae can either mature into adults within the host's intestine or be passed in the feces and then develop into infective larvae on the outside. The infective larvae can penetrate the skin of a new host, enter the bloodstream, and migrate to the lungs, from where they are coughed up and swallowed, returning to the intestine to mature. This complex life cycle is known as "heterogonic" or "discontinuous."
Infection with Strongyloides ratti can cause symptoms such as diarrhea, weight loss, and intestinal bleeding in rats. In immunocompromised individuals, the parasite can also infect humans and cause a similar disease called "strongyloidiasis," which can be asymptomatic or lead to severe complications if left untreated.
It's worth noting that Strongyloides ratti is not a human pathogen and it's mainly used as a laboratory model for studying the biology of Strongyloides stercoralis, a closely related species that infects humans.
Protozoan infections are diseases caused by microscopic, single-celled organisms known as protozoa. These parasites can enter the human body through contaminated food, water, or contact with an infected person or animal. Once inside the body, they can multiply and cause a range of symptoms depending on the type of protozoan and where it infects in the body. Some common protozoan infections include malaria, giardiasis, amoebiasis, and toxoplasmosis. Symptoms can vary widely but may include diarrhea, abdominal pain, fever, fatigue, and skin rashes. Treatment typically involves the use of antiprotozoal medications to kill the parasites and alleviate symptoms.